Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre studyWalter Reinisch, Fabio Cataldi, Tara McDonnell Moorehead et al.|Gut|2015Cited by 157